Iran is among the countries with infertility treatment equipment; Sattari: We have become one of the valuable poles in this field
In the presence of Sorena Sattari, Vice President for Science and Technology, infertility treatment equipment was unveiled to make Iran one of the countries holding this technology.
The Vice President for Science and Technology said at the ceremony that the knowledge base in the field of stem cell technology has now reached a significant number and weight, adding: "We have 150 companies in the field of stem cells, of which 105 are knowledge-based companies."
Sattari, stating that we have witnessed significant changes in this field by knowledge-based companies, continued: "Fortunately, Iran has become one of the valuable poles in the field of stem cells and infertility treatment technologies." This process should be followed by the flourishing of research activities and paving the way for the commercialization of innovative ideas.
The Head of the Stem Cell Science and Technology Development Headquarters said that the process of supporting knowledge-based and technology companies in this field will continued: Products have been produced in this knowledge-based company and with continuous and serious support for the innovation and technology ecosystem, we try to develop the technologies in this field.
No need to import key infertility treatment products According to this report, 30 final products finalized by the experts and researchers of Ravan Sazeh Knowledge-Based Company were officially introduced into the consumption cycle by the Vice President for Science and Technology.
With the production of diagnostic kits, culture media, growth media, and thawing and freezing environments for sperm, eggs and embryos, Iran has become one of the countries producing equipment and consumables needed by infertility treatment centers.
The equipment and consumables used in infertility treatment centers are mostly imported and cover more than 50% of the treatment costs. Localization of knowledge of production of these materials, in addition to cutting dependence on foreign countries and saving foreign exchange, allows it to be exported to countries in the region and Iran's neighbors and its high foreign exchange earnings.
Also, easy, timely and continuous access to these devices and materials, as well as their reasonable price and high quality compared to foreign counterparts, significantly reduce costs and improve the quality of treatment for the benefit of patients.
Ravan Sazeh Company is currently studying and researching on the production of culture media required by the centers for the development and technologies of stem cells, and the experimental production of these products will begin in 1400.
Ravan Sazeh Company has provided the participation of 20 clinics as investors and consumers in order to complete the value chain and create a consumer market for these products.
Report from the Communication and Information Center of the Vice President for Science and Technology
ارسال به دوستان